Krystal Biotech buy Guggenheim
Start price
28.02.23
/
50%
€77.50
Target price
28.02.24
€95.04
Performance (%)
93.55%
End price
29.02.24
€150.00
Summary
This prediction ended on 29.02.24 with a price of €150.00. With a performance of 93.55% the BUY prediction by Guggenheim was a big success. Guggenheim has a follow-up prediction for Krystal Biotech where he still thinks Krystal Biotech is a Buy. Guggenheim has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Krystal Biotech | 3.583% | 3.583% | 99.139% |
| iShares Core DAX® | 2.831% | 1.236% | 14.788% |
| iShares Nasdaq 100 | 2.918% | 0.640% | 40.290% |
| iShares Nikkei 225® | 2.007% | -2.135% | 19.861% |
| iShares S&P 500 | 2.257% | 0.451% | 30.090% |
Comments by Guggenheim for this prediction
In the thread Krystal Biotech diskutieren
Krystal Biotech, Inc. (NASDAQ: KRYS) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $101.00 price target on the stock.
Ratings data for KRYS provided by MarketBeat
In the thread Trading Krystal Biotech
Die von Guggenheim gewählte maximale Laufzeit wurde überschritten